Rani Therapeutics Holdings, Inc.
RANI Nasdaq
SEC CIK 1856725
Follow Rani Therapeutics
Weekly email: filings, results
Revenue, last quarter
$1.7M
Net income
−$7.7M
−42.8% vs same quarter last year
EPS, diluted
−$0.04
+66.7% vs same quarter last year
Operating cash flow
−$7.8M
−53.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $1.6M | −$29.7M |
| FY24 | $1M | −$30M |
| FY23 | $0 | −$34M |
| FY22 | $0 | −$30.6M |
| FY21 | $2.7M | −$8.3M |
| FY20 | $462K | −$16.7M |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −2346% | −1817.1% |
| FY24 | −5186.2% | −2920% |
| FY23 | - | - |
| FY22 | - | - |
| FY21 | −1899.1% | −306.6% |
| FY20 | −3581% | −3615.4% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$18.8M |
| FY24 | −$35.8M |
| FY23 | −$52.5M |
| FY22 | −$48.1M |
| FY21 | −$32.8M |
| FY20 | −$16.2M |
- Rani Therapeutics
- Healthcare median
Show the numbers
| Year | Rani Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −1817.1% | −30.6% |
| FY24 | −2920% | −47% |
| FY23 | - | −58% |
| FY22 | - | −80.4% |
| FY21 | −306.6% | −71.9% |
| FY20 | −3615.4% | −62.2% |